Skip to content
Friday 14 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,772.67
-0.56%
DAX
26,299.74
-0.12%
CAC 40
8,650.56
0.00%
STOXX 50
6,545.47
+0.18%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 17 March 2021 10:07 am  |  Updated:  Wednesday 17 March 2021 10:09 am

EU leaders promise to U-turn on Astrazeneca ban if regulator clears it

By: Poppy Wood

Add as a preferred source on Google
Leaders Attend European Council Meeting
French President Emmanuel Macron has said France will drop its suspension of the Astrazeneca vaccine if it gets the all-clear from the EU's medicines regulator

France and Italy have signalled that they are prepared to U-turn on their suspension of the Astrazeneca Covid vaccine if the European regulator declares it is “firmly convinced” over the jab’s safety.

French President Emmanuel Macron and new Italian Prime Minister Mario Draghi said they would “promptly restart the administration of the Astrazeneca vaccine” if it was cleared by the European Medicines Agency (EMA) tomorrow.

Fifteen European countries have issued a temporary ban on the Covid vaccine made by the Cambridge-based company after several reports of blood clots among patients who had received the jab.

Sweden became the latest nation to join the growing list of countries suspending the vaccine yesterday. No blood clot-related cases have been reported in Sweden but neighbouring Norway and Denmark have each reported one death.

In a press conference yesterday, the EMA said there was “no indication” that Astrazeneca’s Covid vaccine causes blood clots among patients.

“We know that many thousands of people develop thousands of clots annually for many different reasons”, she said Emer Cooke, executive director of the EMA.

She said the agency remains “firmly convinced” that the benefits of the Astrazeneca vaccine outweigh the risk of side-effects, adding that the number of thromboembolic was the normal level among the general European population. The EMA will make a decision on whether to order a continent-wide suspension of the jab tomorrow.

The World Health Organisation (WHO) has also called on countries to continue using the vaccine as investigations into the reports continue.

Read more

Astrazeneca share price tumbles on $400bn megamerger talks

Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure

But suspensions of the jab across the bloc have sparked concern that the EU’s already sluggish vaccine rollout could be slowed even further.

Just 8.5 per cent of Europeans have received their first dose of a Covid vaccine, according to the European Centre for Disease Prevention and Control’s Covid-19 Vaccine Tracker.

That compares to 24.8m people who have received their first injection in the UK — equivalent to around 37 per cent of Britain’s population.

The European Commission has urged governments to stop sitting on vaccine stockpiles as infection rates rise. Countries such as Germany, France and The Netherlands have distributed around half of their total supplies of the Astrazeneca vaccine, despite calls to speed up the vaccine rollout.

“We are racing against time and the rollout of vaccination is more than ever key to decrease the number of infected people as much as possible,” said Stella Kyriakides, the EU’s health commissioner.

Millions of Italians entered fresh restrictions on Monday following a 10 per cent spike in Covid cases last week, with the country set to enter its third nationwide lockdown over the Easter weekend next month.

Italy has used up all of its Pfizer doses as it scrambles to vaccinate the population before cases spread across the country, but just two-thirds of the Astrazeneca supplies delivered to the nation.

Nicola Magrini, head of Italy’s medicines agency, said that the decision to suspend vaccinations was “a political one” that Rome had reached only “because several European countries, including Germany and France, preferred to interrupt”.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Revolut takes flight with launch of new airport lounges

  • It’s not just Jason Arday, most of sociology is a scam

  • IT consultant ordered to pay £50,000 after being accused of stealing Soho House members’ personal details

  • As it happened: FTSE 100 falls as Iran and US clash over Strait of Hormuz; Oil stockpiles ‘rapidly depleting’

More from Morning Wire

  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

    Markets
    Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook